LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

Search

Relay Therapeutics Inc

Abrir

SetorSaúde

4.49 6.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.05

Máximo

4.52

Indicadores-chave

By Trading Economics

Rendimento

6.7M

-70M

Vendas

-7M

677K

Margem de lucro

-10,395.126

Funcionários

197

EBITDA

8M

-77M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+231.96% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

74M

700M

Abertura anterior

-1.66

Fecho anterior

4.49

Sentimento de Notícias

By Acuity

50%

50%

167 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Relay Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de set. de 2025, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 de set. de 2025, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 de set. de 2025, 21:59 UTC

Ganhos

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 de set. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 de set. de 2025, 23:39 UTC

Conversa de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 de set. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 de set. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 de set. de 2025, 21:00 UTC

Ganhos

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 de set. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 de set. de 2025, 18:43 UTC

Conversa de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 de set. de 2025, 18:38 UTC

Conversa de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 de set. de 2025, 18:20 UTC

Conversa de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 de set. de 2025, 18:14 UTC

Conversa de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 de set. de 2025, 17:59 UTC

Conversa de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 de set. de 2025, 17:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 de set. de 2025, 17:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 de set. de 2025, 16:51 UTC

Ganhos

Correct: Exor 1H Net Loss -EUR624M

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 de set. de 2025, 16:25 UTC

Ganhos

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 de set. de 2025, 16:23 UTC

Ganhos

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparação entre Pares

Variação de preço

Relay Therapeutics Inc Previsão

Preço-alvo

By TipRanks

231.96% parte superior

Previsão para 12 meses

Média 13.71 USD  231.96%

Máximo 19 USD

Mínimo 4 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Relay Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

7

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.88 / 3.285Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

167 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat